Scleroderma Completed Phase 3 Trials for Fasudil (DB08162)

Also known as: Dermatosclerosis

IndicationStatusPhase
DBCOND0013449 (Scleroderma)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00498615A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's PhenomenonTreatment